Site icon pharmaceutical daily

Rocket Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights

– First Patient Dosed in RP-A501 Trial for Danon Disease –

– Multi-platform Gene Therapy Pipeline Advances with Four Rocket-sponsored Programs in the Clinic by Year End –

NEW YORK–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, reports financial results for the quarter ended June 30, 2019, and provides an update on the Company’s recent pipeline developments, as well as upcoming milestones.

“2019 is a transformative year for Rocket as we transition to a registrational-stage development company focused on the growth of our multi-platform gene therapy pipeline,” said Gaurav Shah, M.D., Chief Executive Officer and President of Rocket. “This quarter, we made a lot of progress, and we now have three Rocket-sponsored gene therapy programs in the clinic, including our first AAV gene therapy program. The initiation of our Phase 1 clinical trial for Danon disease marked an important milestone for Rocket as we advanced the first AAV gene therapy for a monogenic heart failure syndrome into the clinic. With each clinical milestone, we are one step closer to rapidly providing potentially curative treatments to patients severely in need.”

Recent Pipeline Developments

Anticipated Milestones

Upcoming Investor Conferences

Second Quarter 2019 Financial Results

Financial Guidance

Exit mobile version